EA201890494A1 - Способы лечения вирусных инфекций arenaviridae и coronaviridae - Google Patents

Способы лечения вирусных инфекций arenaviridae и coronaviridae

Info

Publication number
EA201890494A1
EA201890494A1 EA201890494A EA201890494A EA201890494A1 EA 201890494 A1 EA201890494 A1 EA 201890494A1 EA 201890494 A EA201890494 A EA 201890494A EA 201890494 A EA201890494 A EA 201890494A EA 201890494 A1 EA201890494 A1 EA 201890494A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
arenaviridae
coronaviridae
viral infections
treating viral
Prior art date
Application number
EA201890494A
Other languages
English (en)
Other versions
EA038141B1 (ru
Inventor
Майкл О'Нил Ханрахан Кларк
Джой Ян Фэн
Роберт Джордан
Ричард Л. Макман
Эдриан С. Рэй
Дастин Сигель
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201890494A1 publication Critical patent/EA201890494A1/ru
Publication of EA038141B1 publication Critical patent/EA038141B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Предложены способы лечения инфекций вирусов Arenaviridae и Coronaviridae путем введения нуклеозидов формулы Iгде сахар нуклеозида замещен в положении 1', и их пролекарств. Предложенные соединения, композиции и способы, в частности, пригодны для применения для лечения инфекций, вызванных вирусом Ласса и вирусом Хунин.
EA201890494A 2015-09-16 2016-09-16 Способы лечения вирусных инфекций arenaviridae и coronaviridae EA038141B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562219302P 2015-09-16 2015-09-16
US201562239696P 2015-10-09 2015-10-09
PCT/US2016/052092 WO2017049060A1 (en) 2015-09-16 2016-09-16 Methods for treating arenaviridae and coronaviridae virus infections

Publications (2)

Publication Number Publication Date
EA201890494A1 true EA201890494A1 (ru) 2018-10-31
EA038141B1 EA038141B1 (ru) 2021-07-13

Family

ID=56997582

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890494A EA038141B1 (ru) 2015-09-16 2016-09-16 Способы лечения вирусных инфекций arenaviridae и coronaviridae

Country Status (24)

Country Link
US (5) US10251904B2 (ru)
EP (3) EP3349758B1 (ru)
JP (4) JP6742403B2 (ru)
KR (1) KR20180050742A (ru)
CN (5) CN114366745A (ru)
AU (3) AU2016323604B2 (ru)
BR (2) BR112018005048B8 (ru)
CA (1) CA2998189C (ru)
CY (1) CY1125089T1 (ru)
DK (2) DK3349758T3 (ru)
EA (1) EA038141B1 (ru)
ES (2) ES2909419T3 (ru)
HK (3) HK1255732A1 (ru)
HR (2) HRP20220740T1 (ru)
HU (2) HUE058737T2 (ru)
LT (2) LT3785717T (ru)
MA (2) MA52371A (ru)
MX (2) MX2021005087A (ru)
PL (2) PL3785717T3 (ru)
PT (2) PT3349758T (ru)
SG (2) SG10202001878WA (ru)
SI (2) SI3349758T1 (ru)
TW (1) TW201733595A (ru)
WO (1) WO2017049060A1 (ru)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
PL3785717T3 (pl) 2015-09-16 2022-05-02 Gilead Sciences, Inc. Sposoby leczenia infekcji coronaviridae
WO2018089306A1 (en) 2016-11-10 2018-05-17 Oyagen, Inc. Methods of treating and inhibiting ebola virus infection
CN110869028B (zh) * 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
JP2020518578A (ja) 2017-05-01 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
MA50172A (fr) 2017-09-18 2021-04-07 Janssen Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN110724174B (zh) * 2019-09-10 2021-02-05 广州六顺生物科技股份有限公司 吡咯并三嗪类化合物、组合物及其应用
CN111265532A (zh) * 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11738025B2 (en) 2020-02-04 2023-08-29 Oyagen, Inc. Method for treating coronavirus infections
TW202322824A (zh) 2020-02-18 2023-06-16 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) * 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN113292565B (zh) * 2020-02-24 2023-01-31 浙江森科建设有限公司 核苷类化合物及其制备方法和应用
WO2021168930A1 (zh) * 2020-02-25 2021-09-02 顾世海 一种瑞德西韦的片剂及其制备方法
US10874687B1 (en) * 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN111205294B (zh) * 2020-02-27 2021-10-01 江苏阿尔法药业股份有限公司 一种瑞德西韦中间体的制备方法
WO2021173713A1 (en) * 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN111233929B (zh) * 2020-02-28 2023-02-28 成都阿奇生物医药科技有限公司 一种核苷类似物的氘代物及其制备方法和用途
US20230124467A1 (en) * 2020-03-03 2023-04-20 Mios Pharmaceuticals Limited Compounds and methods for treating diseases and/or conditions caused by coronavirus
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法
CN111116656A (zh) * 2020-03-04 2020-05-08 江苏福瑞康泰药业有限公司 一种瑞德西韦的制备方法
CN111269248A (zh) * 2020-03-05 2020-06-12 江苏福瑞康泰药业有限公司 一种核苷氨基磷酸酯类药物母液回收的新方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
CN111393478B (zh) * 2020-03-13 2023-05-26 深圳市宝安区新材料研究院 一种瑞德西韦的合成方法
WO2021186438A1 (en) * 2020-03-16 2021-09-23 Bar-Ilan University Molecules that target proteins of coronaviruses and uses thereof as anti-viral "cocktail"
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN113491673A (zh) * 2020-04-07 2021-10-12 齐鲁制药有限公司 一种含有瑞德西韦的药物组合物
CN113811309B (zh) * 2020-04-13 2023-05-05 山东华铂凯盛生物科技有限公司 用于治疗病毒感染的聚合物制剂及制备方法和用途
US20230285434A1 (en) * 2020-04-14 2023-09-14 Oyagen, Inc. Method for treating arenaviridae infections
CN111848679A (zh) * 2020-04-17 2020-10-30 山东科巢生物制药有限公司 一种利用微通道反应技术合成瑞德西韦的方法
CN113521020B (zh) * 2020-04-18 2023-05-02 齐鲁制药有限公司 一种含有水溶性酸的瑞德西韦固体剂型
CN112778310A (zh) 2020-04-20 2021-05-11 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN111393243B (zh) * 2020-04-22 2022-12-13 深圳市宝安区新材料研究院 一种磷手性核苷类药物的合成方法及该方法得到的药物
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
CN111494349A (zh) * 2020-04-30 2020-08-07 中国人民解放军空军军医大学 一种瑞德西韦口腔速溶膜及制备方法
CN113633617A (zh) * 2020-05-11 2021-11-12 齐鲁制药有限公司 一种含有瑞德西韦的固体分散体、固体剂型及制备方法
CA3176914A1 (en) * 2020-05-20 2021-11-25 Chandanmal pukhraj BOTHRA Novel composition for the treatment of viral infections
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
US11020349B1 (en) * 2020-07-14 2021-06-01 Jubilant Generics Limited Transmucosal dosage forms of remdesivir
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
IN202011022634A (ru) * 2020-05-29 2020-10-09 Jubilant Generics Limited
WO2021240543A1 (en) * 2020-05-29 2021-12-02 Jubilant Generics Limited Transmucosal pharmaceutical compositions of antiviral drugs
CN111620909B (zh) * 2020-06-05 2022-12-02 广东中科药物研究有限公司 一种瑞德西韦的前体药物及其制备方法与应用
US11377456B2 (en) 2020-06-11 2022-07-05 Apotex Inc. Crystalline form of Remdesivir
US20210393663A1 (en) * 2020-06-23 2021-12-23 Cai Gu Huang Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
CN111875638A (zh) * 2020-07-16 2020-11-03 江苏省原子医学研究所 一种瑞德西韦衍生物的制备方法、瑞德西韦衍生物及其应用
CN111961079A (zh) * 2020-07-17 2020-11-20 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和应用
EP4189123A1 (en) * 2020-07-27 2023-06-07 Microbio Pty Ltd A detection method for viral replication
TW202233204A (zh) 2020-08-27 2022-09-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法
CN112358504A (zh) * 2020-09-28 2021-02-12 南京正济医药研究有限公司 一种瑞德西韦有关物质及其制备方法和用途
CN112194681A (zh) * 2020-09-29 2021-01-08 佛山科学技术学院 核苷酸长链氨基磷酸酯化合物、其药物组合物及其制备方法和应用
CN112194680A (zh) * 2020-09-29 2021-01-08 佛山科学技术学院 核苷酸氨基磷酸酯化合物、其药物组合物及其制备方法和应用
US11612614B2 (en) * 2020-10-20 2023-03-28 Anzalp Pharmasolutions Pvt. Ltd. Isomorphs of Remdesivir and methods for synthesis of same
CN112300236A (zh) * 2020-10-21 2021-02-02 佛山科学技术学院 核苷酸混合氨基磷酸酯化合物、其药物组合物及其应用
CN113735862B (zh) * 2020-12-30 2024-02-02 南方科技大学 一种治疗病毒感染的核苷类化合物及其用途
CN113754665B (zh) * 2020-12-30 2022-08-19 南方科技大学 一种核苷类化合物的制备方法
US20220241300A1 (en) * 2021-01-20 2022-08-04 Regents Of The University Of Minnesota Next generation remdesivir antivirals
WO2022166581A1 (zh) * 2021-02-07 2022-08-11 石家庄迪斯凯威医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
CN113105504A (zh) * 2021-03-30 2021-07-13 澳门科技大学 Remdesivir衍生物、其类似物及其制备方法与应用
CN117120444A (zh) 2021-04-16 2023-11-24 吉利德科学公司 使用酰胺制备卡巴核苷的方法
CN115947758A (zh) * 2021-10-07 2023-04-11 南京知和医药科技有限公司 一种核苷酸衍生物及其药物组合物和用途
CN114213366A (zh) * 2022-01-17 2022-03-22 江西师范大学 一种氟代糖内酯合成方法
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2023194840A1 (en) 2022-04-05 2023-10-12 Unichem Laboratories Limited Substituted tricyclic compounds and their use in covid-19
US20240051962A1 (en) * 2022-06-29 2024-02-15 Gilead Sciences, Inc. Solid forms of a nucleoside analogue and uses thereof
US11655255B2 (en) 2022-10-17 2023-05-23 Sph No.1 Biochemical & Pharmaceutical Co., Ltd. Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
ATE167679T1 (de) 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
JPH1017629A (ja) 1996-07-04 1998-01-20 Kayaku Akzo Kk ハードコート用樹脂組成物及びその硬化方法
US6887707B2 (en) 1996-10-28 2005-05-03 University Of Washington Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
ZA991572B (en) 1998-03-03 1999-09-03 Novo Nordisk As New salt forms of (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-(N-methyl-N-((1R)-1-(methylcarbamoyl)-2-phenylethyl)carbamoy L)-2-(2-naphthyl)ethyl)amide.
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
WO1999049873A1 (en) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides with antiviral and anticancer activity
EP1121361B1 (en) 1998-10-16 2007-08-29 Merck Sharp & Dohme Limited Pyrazolo-triazine derivatives as ligands for gaba receptors
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
CA2376016A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Oligonucleotide synthesis with lewis acids as activators
AUPQ105499A0 (en) 1999-06-18 1999-07-08 Biota Scientific Management Pty Ltd Antiviral agents
WO2001019375A1 (en) 1999-09-15 2001-03-22 Biocryst Pharmaceuticals, Inc. Inhibiting t-cell proliferation
WO2001032153A2 (en) 1999-11-04 2001-05-10 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
AU2001235278A1 (en) 2000-02-18 2001-08-27 Shire Biochem Inc Method for the treatment or prevention of flavivirus infections using nucleoside analogues
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
OA12382A (en) 2000-05-26 2006-04-17 Novirio Pharmaceuticals Ltd Methods and compositions for treating flavivirusesand pestiviruses.
ES2536972T5 (es) 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR100905221B1 (ko) 2000-10-18 2009-07-01 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
EP1355916B1 (en) 2001-01-22 2007-01-10 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE10145223A1 (de) 2001-09-13 2003-04-03 Basf Ag Verfahren zur Herstellung von meso-Zeaxanthin
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
US7285658B2 (en) 2002-02-28 2007-10-23 Biota, Inc. Nucleotide mimics and their prodrugs
US20040138170A1 (en) 2002-03-06 2004-07-15 Montgomery John A. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210127D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
RU2004135392A (ru) 2002-05-06 2005-06-27 Дженелэбс Текнолоджиз, Инк. (Us) Производные нуклеозидов для лечения инфекции, вызываемой вирусом гепатита с
AU2003233667A1 (en) 2002-05-23 2003-12-12 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
US7429565B2 (en) 2003-04-25 2008-09-30 Gilead Sciences, Inc. Antiviral phosphonate analogs
NZ544671A (en) 2003-06-26 2009-02-28 Biotron Ltd Antiviral compounds and methods
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
DE602004028841D1 (de) 2003-07-25 2010-10-07 Centre Nat Rech Scient Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
EP1660511B1 (en) 2003-08-27 2010-11-03 Biota Scientific Management Pty. Ltd. Novel tricyclic nucleosides or nucleotides as therapeutic agents
SI1730131T1 (sl) 2004-03-16 2012-08-31 Boehringer Ingelheim Int Glukopiranozil-substituirani benzenski derivati, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo
EP1758453B1 (en) 2004-06-15 2014-07-16 Merck Sharp & Dohme Corp. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
WO2006002231A1 (en) 2004-06-22 2006-01-05 Biocryst Pharmaceuticals, Inc. Aza nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
RU2433124C2 (ru) 2004-09-14 2011-11-10 Фармассет, Инк. Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных
CN101043893A (zh) 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
EP1804812A4 (en) 2004-10-21 2009-09-02 Merck & Co Inc FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
CA2585079A1 (en) 2004-10-29 2006-05-11 Biocryst Pharmaceuticals, Inc. Therapeutic furopyrimidines and thienopyrimidines
EP1828216B1 (en) 2004-12-16 2008-09-10 Boehringer Ingelheim International GmbH Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
EP1858889A1 (en) 2005-03-08 2007-11-28 Biota Scientific Management Pty. Ltd. Bicyclic nucleosides and nucleotides as therapeutic agents
AU2006230023A1 (en) 2005-03-29 2006-10-05 Biocryst Pharmaceuticals, Inc. Hepatitis C therapies
WO2006116557A1 (en) 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
DK1902017T3 (da) 2005-06-24 2014-06-30 Biotron Ltd Antivirale acylguanidinforbindelser
CA2665370A1 (en) 2005-10-03 2007-04-12 University Health Network Odcase inhibitors for the treatment of malaria
ES2401099T3 (es) 2005-11-02 2013-04-16 Bayer Intellectual Property Gmbh Pirrolo[2,1-F] [1,2,4]-triazin-4-ilaminas como inhibidores de la quinasa IGF-1R para el tratamiento del cáncer y de otras enfermedades hiperproliferativas
KR101191682B1 (ko) 2005-12-01 2012-10-16 바실리어 파마슈티카 아게 에폭시부탄올 중간체의 제조 방법
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
JP4979710B2 (ja) 2005-12-09 2012-07-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗ウイルスヌクレオシド
EP1971331A2 (en) 2005-12-09 2008-09-24 Basilea Pharmaceutica AG 4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
JP2009526850A (ja) 2006-02-14 2009-07-23 メルク エンド カムパニー インコーポレーテッド Ｒｎａ依存性ｒｎａウイルス感染を治療するためのヌクレオシドアリールホスホルアミデート
WO2007097991A2 (en) 2006-02-16 2007-08-30 Pharmasset, Inc. Methods and kits for dosing of antiviral agents
DE102006015378A1 (de) 2006-04-03 2007-10-04 Ludwig-Maximilians-Universität München Verfahren zur Synthese von Organoelementverbindungen
CL2007001427A1 (es) 2006-05-22 2008-05-16 Novartis Ag Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
WO2008005542A2 (en) 2006-07-07 2008-01-10 Gilead Sciences, Inc., Antiviral phosphinate compounds
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
AR063569A1 (es) 2006-11-06 2009-02-04 Boehringer Ingelheim Int Derivados de benzil- benzonitrilo sustituidos con glucopiranosilo medicamentos que contienen a compuestos de este tipo su uso u procedimiento para su fabricacion
WO2008079206A1 (en) 2006-12-20 2008-07-03 Merck & Co., Inc. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
AU2008206406A1 (en) 2007-01-12 2008-07-24 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
JP2010522241A (ja) 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
EP2155758B1 (en) 2007-05-10 2012-08-22 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro[3,4-d]dioxolane compounds for use in the treatment of viral infections and cancer
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
CN101827589B (zh) 2007-08-03 2016-08-17 拜伊特朗有限公司 抗丙型肝炎病毒的组合物及方法
KR101502533B1 (ko) 2007-11-22 2015-03-13 에스케이케미칼주식회사 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
TW200942243A (en) 2008-03-05 2009-10-16 Biocryst Pharm Inc Antiviral therapeutic agents
US8227431B2 (en) 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
SI2937350T1 (en) * 2008-04-23 2018-05-31 Gilead Sciences, Inc. 1'-SUBSTITUTED CARBON-NUCLEOUS ANALOGS FOR ANTIVIRUSAL TREATMENT
US7863291B2 (en) 2008-04-23 2011-01-04 Bristol-Myers Squibb Company Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
WO2010036407A2 (en) 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
PL2396340T3 (pl) 2009-02-10 2014-05-30 Gilead Sciences Inc Analogi karba-nukleozydu do terapii przeciwwirusowych
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
AP2011005929A0 (en) 2009-03-20 2011-10-31 Alios Biopharma Inc Substituted nucleoside and nucleotide analogs.
AU2010230008B2 (en) 2009-03-24 2015-06-04 Biocryst Pharmaceuticals, Inc. Useful pharmaceutical salts of 7-[(3R, 4R)-3-Hydroxy-4-hydroxymethyl-pyrrolidin-1- ylmethyl]-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-one
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
CN102471327A (zh) 2009-07-21 2012-05-23 吉里德科学公司 黄病毒科病毒的抑制剂
LT2480552T (lt) 2009-09-21 2017-02-10 Gilead Sciences, Inc. 2'-fluoru pakeisti karbanukleozidų analogai, skirti antivirusiniam gydymui
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CN102596979B (zh) 2009-09-21 2014-12-10 吉里德科学公司 用于制备1’-取代碳核苷类似物的方法和中间体
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US20120288492A1 (en) 2009-12-28 2012-11-15 Dcb-Usa Llc NOVEL PYRIMIDINE COMPOUNDS AS mTOR AND PI3K INHIBITORS
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
SG186830A1 (en) 2010-07-22 2013-02-28 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
KR101879887B1 (ko) 2010-09-20 2018-07-18 길리애드 사이언시즈, 인코포레이티드 항바이러스 치료용 2'-플루오로 치환된 카바-누클레오시드 유사체
PE20140608A1 (es) 2010-09-22 2014-06-12 Alios Biopharma Inc Analogos de nucleotidos sustituidos
SI2898885T1 (en) 2010-10-15 2018-03-30 Biocryst Pharmaceuticals, Inc. Pyrrolopyrimidine derivatives for use in the treatment of viral infections
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
JP5891241B2 (ja) 2010-12-20 2016-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖを処置するための組合せ
KR20130138840A (ko) 2011-04-13 2013-12-19 머크 샤프 앤드 돔 코포레이션 2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
JP6043338B2 (ja) 2011-04-13 2016-12-14 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス治療用の１’−置換ピリミジンｎ−ヌクレオシド類似体
WO2012158643A1 (en) 2011-05-13 2012-11-22 Ah Usa 42 Llc Hendra and nipah virus g glycoprotein immunogenic compositions
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Pharmasset Llc Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
WO2013084165A1 (en) 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
US20130143835A1 (en) 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
WO2014033617A1 (en) 2012-08-31 2014-03-06 Novartis Ag 2'-ethynyl nucleoside derivatives for treatment of viral infections
PE20150776A1 (es) 2012-09-10 2015-05-21 Hoffmann La Roche 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infeccion del virus de la hepatitis b
WO2014042433A2 (en) 2012-09-14 2014-03-20 Kainos Medicine, Inc. Compounds and compositions for modulating adenosine a3 receptor activity
CA2890905A1 (en) * 2012-11-16 2014-05-22 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
AU2013344757A1 (en) 2012-11-19 2015-05-21 Merck Sharp & Dohme Corp. 2 -alkynyl substituted nucleoside derivatives for treating viral diseases
US9243022B2 (en) 2012-12-21 2016-01-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9283242B2 (en) * 2013-01-22 2016-03-15 Massachusetts Institute Of Technology Uses of dihydro bases
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
EP2984098A2 (en) 2013-04-12 2016-02-17 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
US9542154B2 (en) 2013-06-25 2017-01-10 Intel Corporation Fused multiply add operations using bit masks
UA117375C2 (uk) 2013-09-04 2018-07-25 Медівір Аб Інгібітори полімерази hcv
RS61540B1 (sr) 2013-09-11 2021-04-29 Inst Nat Sante Rech Med Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EP3099685B1 (en) 2014-01-30 2018-04-18 F.Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
CR20160337A (es) 2014-03-07 2016-09-20 Hoffmann La Roche Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
WO2015173164A1 (en) 2014-05-13 2015-11-19 F. Hoffmann-La Roche Ag Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
US9616076B2 (en) 2014-06-02 2017-04-11 The Board Of Regents Of The University Of Texas Systems Methods for treating viral infections using hydrogen sulfide donors
US9504701B2 (en) 2014-06-02 2016-11-29 The Board Of Regents Of The University Of Texas System Methods for treating viral infections using hydrogen sulfide donors
WO2016012470A1 (en) 2014-07-25 2016-01-28 F. Hoffmann-La Roche Ag New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
EP3180319B1 (en) 2014-08-14 2018-10-03 F.Hoffmann-La Roche Ag Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
TWI740546B (zh) 2014-10-29 2021-09-21 美商基利科學股份有限公司 製備核糖苷的方法
US9637485B2 (en) 2014-11-03 2017-05-02 Hoffmann-La Roche Inc. 6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
WO2016102438A1 (en) 2014-12-23 2016-06-30 F. Hoffmann-La Roche Ag Process for the preparation of 4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidine analogues
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
CN107108610B (zh) 2014-12-30 2019-06-04 豪夫迈·罗氏有限公司 用于治疗和预防肝炎b病毒感染的新的四氢吡啶并嘧啶和四氢吡啶并吡啶化合物
EP3240913A1 (en) 2014-12-31 2017-11-08 F. Hoffmann-La Roche AG A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
CN107208102B (zh) 2015-01-27 2021-07-06 豪夫迈·罗氏有限公司 重组hbv cccdna、其产生方法及其用途
CN107207505B (zh) 2015-02-11 2018-12-14 豪夫迈·罗氏有限公司 治疗和预防乙型肝炎病毒感染的 2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
PL3785717T3 (pl) * 2015-09-16 2022-05-02 Gilead Sciences, Inc. Sposoby leczenia infekcji coronaviridae
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
CN108299532B (zh) 2016-12-29 2020-12-22 广东东阳光药业有限公司 一种抗病毒核苷类似物前药及其组合物、用途
WO2018145148A1 (en) 2017-02-08 2018-08-16 Biotron Limited Methods of treating influenza
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
JP2020518578A (ja) 2017-05-01 2020-06-25 ギリアード サイエンシーズ， インコーポレイテッド （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態
TW201919648A (zh) 2017-07-11 2019-06-01 美商基利科學股份有限公司 用於治療病毒感染之含rna聚合酶抑制劑與環糊精的組合物
CN111265532A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
TW202233204A (zh) 2020-08-27 2022-09-01 美商基利科學股份有限公司 用於治療病毒感染之化合物及方法

Also Published As

Publication number Publication date
US20230027727A1 (en) 2023-01-26
US20210393659A1 (en) 2021-12-23
MA42819A (fr) 2018-07-25
MX2018003161A (es) 2018-05-17
PT3785717T (pt) 2022-04-14
PT3349758T (pt) 2022-07-13
HRP20220740T1 (hr) 2022-11-11
SI3349758T1 (sl) 2022-08-31
AU2023200990A1 (en) 2023-03-23
CN115844896A (zh) 2023-03-28
BR122020020217B1 (pt) 2021-08-17
SG10202001878WA (en) 2020-04-29
CN116617233A (zh) 2023-08-22
AU2016323604A1 (en) 2018-03-29
KR20180050742A (ko) 2018-05-15
BR112018005048B8 (pt) 2021-03-23
US10251904B2 (en) 2019-04-09
CA2998189A1 (en) 2017-03-23
TW201733595A (zh) 2017-10-01
DK3349758T3 (da) 2022-06-13
US10695361B2 (en) 2020-06-30
JP2021107431A (ja) 2021-07-29
HK1257628A1 (zh) 2019-10-25
DK3785717T3 (da) 2022-03-21
US11382926B2 (en) 2022-07-12
CN115887465A (zh) 2023-04-04
MX2021005087A (es) 2022-08-18
SI3785717T1 (sl) 2022-04-29
AU2016323604B2 (en) 2020-07-09
PL3785717T3 (pl) 2022-05-02
US11007208B2 (en) 2021-05-18
HUE057928T2 (hu) 2022-06-28
CA2998189C (en) 2021-08-03
PL3349758T3 (pl) 2022-09-12
EP4088718A1 (en) 2022-11-16
BR112018005048B1 (pt) 2021-02-23
EP3349758B1 (en) 2022-04-06
ES2918585T3 (es) 2022-07-19
HUE058737T2 (hu) 2022-09-28
US20200352967A1 (en) 2020-11-12
CY1125089T1 (el) 2023-06-09
EP3785717B1 (en) 2022-01-05
JP2020111587A (ja) 2020-07-27
LT3349758T (lt) 2022-07-11
EP3349758A1 (en) 2018-07-25
JP2023085459A (ja) 2023-06-20
SG10202109869XA (en) 2021-10-28
AU2020233714B2 (en) 2022-11-24
AU2020233714A1 (en) 2020-10-08
HRP20220355T1 (hr) 2022-05-13
EA038141B1 (ru) 2021-07-13
JP7254738B2 (ja) 2023-04-10
MA52371A (fr) 2021-09-22
JP2018531227A (ja) 2018-10-25
HK1255732A1 (zh) 2019-08-23
WO2017049060A1 (en) 2017-03-23
US20170071964A1 (en) 2017-03-16
CN108348526A (zh) 2018-07-31
EP3785717A1 (en) 2021-03-03
JP6742403B2 (ja) 2020-08-19
ES2909419T3 (es) 2022-05-06
CN114366745A (zh) 2022-04-19
US20190255085A1 (en) 2019-08-22
LT3785717T (lt) 2022-04-11
HK1256872A1 (zh) 2019-10-04

Similar Documents

Publication Publication Date Title
EA201890494A1 (ru) Способы лечения вирусных инфекций arenaviridae и coronaviridae
EA201790597A1 (ru) Способы лечения вирусных инфекций filoviridae
EA202090775A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201692535A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201692537A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201690526A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201791886A1 (ru) Антивирусные соединения
EA201691931A1 (ru) 4'-замещенные нуклеозидные ингибиторы обратной транскриптазы
EA201791903A1 (ru) β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
EA201590943A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201691261A1 (ru) Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
EA201391264A1 (ru) 1'-замещенные пиримидиновые n-нуклеозидные аналоги для противовирусного лечения
EA201592075A1 (ru) Замещенные нуклеозиды, нуклеотиды и их аналоги
EA201592184A1 (ru) 4'-фтор-2'-метилзамещенные нуклеозидные производные
EA201890454A1 (ru) Пирролопиримидиновые нуклеозиды и их аналоги, которые можно использовать в качестве противовирусных средств
EA201990628A1 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
EA201790234A1 (ru) 2'-хлораминопиримидиноновые и пиримидиндионовые нуклеозиды
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
EA201592185A1 (ru) 4'-азидо, 3'-дезокси-3'-фторзамещенные нуклеозидные производные
EA201892448A1 (ru) Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения